Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 12, 2009

Primary Completion Date

July 18, 2011

Study Completion Date

July 18, 2011

Conditions

Leukaemia, Myelocytic, Acute

Interventions

DRUG

GSK1120212

Continuous daily oral dosing while on study or disease progression (cycle = 28 days).

DRUG

Gemcitabine

Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.

Trial Locations (2)

GSK Investigational Site, Nashville

GSK Investigational Site, San Antonio